#hepatitis B

A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.

Those who begin antiretrovirals with a higher CD4 count and CD4 to CD8 ratio are more likely to experience immune recovery.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.

This is according to the large randomized controlled START trial.

One researcher argues that the pharmaceutical industry ought to pay greater heed to such risks during drug development.

Born with hemophilia. Diagnosed with hepatitis B at age 6. HIV at age 11. Hep C at age 18. I am the embodiment of a pre-existing condition.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The Centers for Disease Control and Protection (CDC) recommends hepatitis B and C testing for everyone with HIV.

People living with HIV are not getting vaccinated for hepatitis B.

These rates are driven in large part by hepatitis B and C.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

90 days ago, he declared a public health emergency.